Yunyi Bian

1.3k total citations · 1 hit paper
59 papers, 864 citations indexed

About

Yunyi Bian is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Yunyi Bian has authored 59 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 35 papers in Molecular Biology and 25 papers in Cancer Research. Recurrent topics in Yunyi Bian's work include Ferroptosis and cancer prognosis (28 papers), RNA modifications and cancer (22 papers) and Cancer-related molecular mechanisms research (12 papers). Yunyi Bian is often cited by papers focused on Ferroptosis and cancer prognosis (28 papers), RNA modifications and cancer (22 papers) and Cancer-related molecular mechanisms research (12 papers). Yunyi Bian collaborates with scholars based in China, United States and United Kingdom. Yunyi Bian's co-authors include Cheng Zhan, Guoshu Bi, Jiaqi Liang, Qun Wang, Zhencong Chen, Yiwei Huang, Mengnan Zhao, Zhengyang Hu, Qihai Sui and Tao Lu and has published in prestigious journals such as Nature Communications, Cancer Research and Free Radical Biology and Medicine.

In The Last Decade

Yunyi Bian

53 papers receiving 861 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer

2024 69 citations Guoshu Bi, Jiaqi Liang et al. Nature Communications profile →

Peers

Yunyi Bian

PRM

ONCOL

IMMUN

Guoshu Bi China

Caner Ercan Switzerland

Xiaozai Xie China

Libin Sun China

Tianbo Xu China

Liqiao Fan China

Yuxiao Zheng China

Fu-Ju Chou United States

Ren Zhao China

Lais Osmani United States

Guoshu Bi China

Yunyi Bian

707 ×1.3

493 ×1.2

PRM

446 ×1.3

301 ×1.3

ONCOL

142 ×1.4

IMMUN

Citations per year, relative to Yunyi Bian Yunyi Bian (= 1×) peers Guoshu Bi

Countries citing papers authored by Yunyi Bian

Since Specialization

Citations

This map shows the geographic impact of Yunyi Bian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunyi Bian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunyi Bian more than expected).

Fields of papers citing papers by Yunyi Bian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunyi Bian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunyi Bian. The network helps show where Yunyi Bian may publish in the future.

Co-authorship network of co-authors of Yunyi Bian

This figure shows the co-authorship network connecting the top 25 collaborators of Yunyi Bian. A scholar is included among the top collaborators of Yunyi Bian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunyi Bian. Yunyi Bian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liang, Jiaqi, Guoshu Bi, Xiaolong Huang, et al.. (2025). CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer. Cancer Communications. 45(11). 1547–1578.

Bi, Guoshu, Jiaqi Liang, Yunyi Bian, et al.. (2025). Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. Nature Communications. 16(1). 8181–8181. 1 indexed citations

Shan, Guangyao, et al.. (2025). Retinol-driven Gene Signatures Predict Lung Adenocarcinoma Outcomes and Highlight PAICS as a Therapeutic Opportunity. PubMed. 5(5). 535–550.

Bian, Yunyi, Guangyao Shan, Guoshu Bi, et al.. (2025). Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status. Nature Communications. 16(1). 9923–9923.

Cheng, Hongxia, Jiacheng Yin, Yuansheng Zheng, et al.. (2025). NDRG1‐Driven Lactate Accumulation Promotes Lung Adenocarcinoma Progression Through the Induction of an Immunosuppressive Microenvironment. Advanced Science. 12(33). e01238–e01238. 4 indexed citations

Liang, Jiaqi, et al.. (2024). miR‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. Thoracic Cancer. 15(30). 2206–2216. 3 indexed citations

Shan, Guangyao, Yunyi Bian, Guangyu Yao, et al.. (2024). Targeting ALDH2 to augment platinum-based chemosensitivity through ferroptosis in lung adenocarcinoma. Free Radical Biology and Medicine. 224. 310–324. 8 indexed citations

Zhao, Guangyin, Jiaqi Liang, Yuchen Zhang, et al.. (2024). MNT inhibits lung adenocarcinoma ferroptosis and chemosensitivity by suppressing SAT1. Communications Biology. 7(1). 680–680. 8 indexed citations

Bi, Guoshu, Jiaqi Liang, Guangyao Shan, et al.. (2023). Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells. Cancer Research. 83(14). 2387–2404. 37 indexed citations

10.

Valle, Juan W., Ghassan K. Abou‐Alfa, Robin Kate Kelley, et al.. (2023). SO-2 Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial. Annals of Oncology. 34. S162–S162.

11.

Sui, Qihai, Zhengyang Hu, Jiaqi Liang, et al.. (2023). Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma. Cancer Letters. 581. 216497–216497. 14 indexed citations

12.

Zhao, Mengnan, Tao Lu, Guoshu Bi, et al.. (2023). PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway/ferroptosis. Biomedicine & Pharmacotherapy. 168. 115711–115711. 30 indexed citations

13.

Zhang, Huan, Yunyi Bian, Jiaqi Liang, et al.. (2023). Hepatic nuclear factor 4 alpha promotes the ferroptosis of lung adenocarcinoma via transcriptional activation of cytochrome P450 oxidoreductase. PeerJ. 11. e15377–e15377. 5 indexed citations

14.

Zhang, Yu, et al.. (2021). Effect of dietary complex Chinese herbal medicine on growth performance, digestive enzyme activities in tissues and expression of genes involved in the digestive enzymes and antioxidant enzymes and bacterial challenge in Litopenaeus vannamei. Aquaculture Research. 52(12). 6741–6750. 15 indexed citations

15.

Chen, Zhencong, Yiwei Huang, Zhengyang Hu, et al.. (2021). Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy. Oncogenesis. 10(10). 71–71. 30 indexed citations

16.

Hu, Zhengyang, Guoshu Bi, Qihai Sui, et al.. (2020). Analyses of multi-omics differences between patients with high and low PD1/PDL1 expression in lung squamous cell carcinoma. International Immunopharmacology. 88. 106910–106910. 7 indexed citations

17.

Chen, Zhencong, Mengnan Zhao, Ming Li, et al.. (2020). Identification of differentially expressed genes in lung adenocarcinoma cells using single-cell RNA sequencing not detected using traditional RNA sequencing and microarray. Laboratory Investigation. 100(10). 1318–1329. 23 indexed citations

18.

Liang, Jiaqi, Ming Li, Qihai Sui, et al.. (2020). Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis. Translational Lung Cancer Research. 9(4). 1302–1323. 23 indexed citations

19.

Xi, Junjie, Zhengyang Hu, Jiaqi Liang, et al.. (2020). Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I–IIIA non-small cell lung cancer: a propensity-matched analysis. Journal of Thoracic Disease. 12(6). 3043–3056. 8 indexed citations

20.

Bi, Guoshu, Tao Lu, Guangyu Yao, et al.. (2019). <p>The Prognostic Value Of Lymph Node Ratio In Patients With N2 Stage Lung Squamous Cell Carcinoma: A Nomogram And Heat Map Approach</p>. Cancer Management and Research. Volume 11. 9427–9437. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact